A Comparative Pharmaco-Clinical Study of Arjuna and Manjishtha w.s.r. to Vyanga
Abstract
In Ayurveda Vyanga is a disease which is firstly described by Acharya Sushruta under Kshudra Roga. According to Acharya Sushruta Krodha and Shoka are responsible for development of Vyanga, as these psychological factors vitiate Pitta and Vata Dosha which then travel and get localized on facial skin and leads to development of Nirujam, Tanu Shyava Varna Mandala. Ayurveda is very effective in treating skin disorders and skin is also mentioned as a route of drug administration in terms of Bahiparimarajan Chikitsa. Acharya Sharangdhara has mentioned various Lepa formulations for various skin diseases; among them he has quoted Arjuna Twak Churna and Manjishtha Churna for treatment of Vyanga. It is easy to understand about Manjishtha because it is a very well known established Varnya drug, but regarding Arjuna it was very much important to trail it clinically as it is an established drug for heart. From Dravyaguna point of view it was very important to study Arjuna, that how it would have broken the pathogenesis of Vyanga, what are the major chemicals present in Arjuna that work on hyper pigmentation. So a proper revalidation of Shastrokta quote of Acharya Sharangdhara was done by clinical trial and pharmacognostical and HPTLC analysis of Arjuna and Manjishtha.
Downloads
References
Sharma Anantaram Sushruta samhita, Susrutvimarshni Hindi commentary Subharati Prakashana, Varanasi 2004.pg. no. 288.
Parashar Shri Radha Krishna, Editor, Acharya Sharangdhar, Sharangdhar Samhita, 3rd Ed; Baidhyanath Ayurveda Bhawan, Patna.
Gupta Kaviraja Atrideva, Astanga Hridaya, of Vagbhatta, Edited with the Vidyotini Hindi commentary; Chaukhamba Sanskrit Sansthan, Varanasi, 13th Edition, 2000. pg no 889-890.
Boissy RE, Nordlund JJ. Cutaneous medicine and surgery In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors, cutaneous medicine and surgery. Pheladelphia: w.b. saunders Co; 1996. Pp. 1203-18.
Yamaguchi Y, Brenner M, Hearing VJ. The regulation of skin pigmentation. J Biol Chem. 2007;282:27557- 61[pubmed].
Petit I, Pierard GE, skin lightening products revisited. Int J Cosmet sci. 2006;20:921-34.[pubmed]
Parvez S, Kang M, Chung HS, Cho C, Hong MC, Shin MK, et al. survey and mechanism of skin depigmentation and lightening agents. Phytoether Res. 2006;20:921- 34.[pubmed]
Tripathi KD, Essentials of medical pharmacology, seventh edition, reprint 2015, Jaypee brothers medical publishers, new delhi,pg no 37.
Tripathi KD, Essentials of medical pharmacology, seventh edition, reprint 2015, Jaypee brothers medical publishers, new delhi, pg no 38-39.
Kim Y], uyama H. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell mol.life.sci. 2005;62:1707-1723[ pubmed](google scholar).
Hanamura T, uchida E, Akoi H. skin lightening effect of ellagic acid .biosci. biotechnol.biochem.2008;72:3211- 3218.PMID 26899308 [indexed for medline].
Chen X-X1 shi Y, chai W-M, Feng H-L, Zhuang J-X, Chen Q-X (2014) tannins as tyrosinase inhibitors: PLOSONE 9(3): e91809 doi:10:1371/ journal. Pone. 0091809.
Kazuomi sato and Masaru Toriyama, depgmenting effect of catechins molecules 2009,14,4425- 4432;doi:10.3390/molecules14114425.
Herbtime http://www.wordpress.com/2010/02/08/Manjishtharubia cordifolia.
Vaibhav S, Lakshman K. tyrosinase inhibitory activity of selected Indian herbs. Int J Res Pharm Biomed Sci. 2012;3:977-82.[google scholar].
Journal of Ayurveda and Integrated Medical Sciences (JAIMS) retains the copyright of the contents of this journal but grant the readers the right to use the contents with terms and conditions under a creative common attribution licenses 4 of Attribution, Share Alike and Non-commercial type (CC BY-NC-SA) that allows copy, distribute, display, and perform the work and make derivative works based on it only for non-commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
